Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study

Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study

Background: Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the...

Full description

Bibliographic Details
Main Authors: Shih-Yi Lin, Cheng-Li Lin, Cheng-Chieh Lin, Wu-Huei Hsu, Chung-Y. Hsu, Chia-Hung Kao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Pharmacology
Subjects:
NHIRD: national health insurance
diabetes mellitus (DM)
chronic kidney disease (CKD)
dihydropyridine calcium channel blockers (DCCBs)
end-stage renal disease (ESRD)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.786203/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.786203/full

Similar Items